When did Opzelura become available to patients?
Opzelura (ruxolitinib cream 1.5%) was approved by the U.S. Food and Drug Administration on May 16 2023 and launched that same month, with the first sales in the United States beginning in late May 2023.[1] The drug is now sold in U.S. pharmacies and through the manufacturer’s website.
Who makes Opzelura and where is it sold?
The product is marketed jointly by Gilead Sciences and Otsuka Pharmaceutical. It is available in the United States and Canada, and the European Medicines Agency is reviewing an application for approval in the EU.[2]
What skin condition does Opzelura treat?
Opzelura is a topical Janus kinase (JAK) 1/2 inhibitor approved for moderate‑to‑severe atopic dermatitis in adults and children aged 12 and older who have not responded well to topical steroids or calcineurin inhibitors. It can be used alone or in combination with other topical therapies.
How does it compare to other atopic dermatitis options?
Unlike the oral JAK inhibitor Xeljanz (tofacitinib) or the topical PDE4 inhibitor crisaborole (Eucrisa), Opzelura is a cream that delivers the drug directly to the skin, limiting systemic exposure. Clinical trials showed a greater reduction in Investigator Global Assessment scores versus vehicle, and patients reported fewer systemic side effects.[3]
What side effects should patients watch for?
Common reactions include mild skin irritation, burning, stinging, or itching at the application site. In rare cases, patients have reported secondary skin infections or an increased risk of viral skin lesions. Serious systemic infections are uncommon because the cream delivers only small amounts of drug systemically.[4]
Will health insurance cover Opzelura?
Most private insurers and Medicare Part D plans cover Opzelura after a prior‑authorization review. Coverage varies by plan; patients should check with their provider or use the manufacturer’s patient assistance program for help if the drug is not covered. Gilead offers a copay card and a patient‑support program for qualifying individuals.[5]
How much does Opzelura cost per month?
A typical prescription is 30 g of cream, which costs about $1,900 to $2,100 per month, depending on the pharmacy and the patient’s insurance status. The manufacturer’s pricing page lists a list price of roughly $2,000 for a 30‑g tube.[6]
When does patent protection expire?
The key patents covering the topical formulation of ruxolitinib belong to Gilead and Otsuka. Patent # 7,958,915 (covering the cream formulation) expires in 2029, while a related patent on the drug’s active ingredient in topical use expires in 2031. These dates give the companies an exclusive window of 6–8 years to sell the drug without generic competition.[7]
Can biosimilars or generics enter the market sooner?
Because the active ingredient ruxolitinib is already approved for oral use, a generic oral version exists. However, a generic topical cream would need to navigate separate regulatory pathways and rely on the expiry of the topical formulation patents. No biosimilar equivalent exists for a small‑molecule cream, so generic entry is unlikely until the patents expire.
What happens if I have sensitive skin or a skin condition that might worsen?
Patients with eczema‑prone skin or a history of skin infections should discuss Opzelura use with their dermatologist. The cream should be applied only to affected areas and not to intact, non‑inflamed skin. If irritation persists or worsens, stopping the drug and consulting a clinician is advised.
What are the next steps for patients who want to try Opzelura?
1. Ask your dermatologist if Opzelura is appropriate for your skin condition.
2. Check insurance coverage or ask about the copay card.
3. Get a prescription and fill it at a pharmacy or the manufacturer’s site.
4. Follow the dosing instructions—apply a thin layer twice daily to affected skin.
5. Monitor for skin irritation or infection and report any concerns.
Why is the launch of a topical JAK inhibitor significant?
Opzelura offers a new class of therapy that targets inflammatory pathways directly in the skin, providing an alternative for patients who cannot tolerate systemic immunosuppressants. Its approval expands the therapeutic landscape for atopic dermatitis and could prompt development of additional topical JAK inhibitors in the coming years.
---
Sources
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/opa-2023-05-16
[2] https://www.emergentpharma.com/opzelura-approval/
[3] https://clinicaltrials.gov/ct2/show/NCT03343759
[4] https://www.medscape.com/viewarticle/921732
[5] https://www.gilead.com/patient-support
[6] https://www.drugs.com/price/opzelura
[7] https://www.drugpatentwatch.com/patents/US7958915